



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/973,576	04/02/98	MALFROY-CAMINE	B 15390-00013U

HM12/0524  
EUGENIA GARRETT-WACKOWSKI  
TOWNSEND & TOWNSEND & CREW  
TWO EMBARCADERO CENTER  
8TH FLOOR  
SAN FRANCISCO CA 94111-3834

EXAMINER

SCHWADRON, R

ART UNIT	PAPER NUMBER
----------	--------------

1644

17

DATE MAILED: 05/24/00

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Office Action Summary

Application No.  
**08/973,576**

Applicant(s)  
**Malfroy-Camine**

Examiner  
**Ron Schwadron, Ph.D.**

Group Art Unit  
**1644**



- ☐ Responsive to communication(s) filed on \_\_\_\_\_.
- ☐ This action is **FINAL**.
- ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claims

- ☒ Claim(s) 1-22 and 24 is/are pending in the application.
- Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- ☒ Claim(s) 1-22 and 24 is/are rejected.
- ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- ☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

- ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_.
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

- ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

- ☐ Notice of References Cited, PTO-892
- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_
- ☐ Interview Summary, PTO-413
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

1. Claims 1-22,24 are under consideration. Claims 11,12,21,22 have been amended.

## RESPONSE TO APPLICANTS ARGUMENTS

2. The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 14-22 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1,2,4-12,24,29-33 of copending application Serial No. 08/483944 for the reasons elaborated in the previous Office Action.

Applicant has indicated that this issue will be addressed at a later date.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner

and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-5,7-10,12-22,24 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the claimed method or product using the lipid glycyldioctadecylamide, does not reasonably provide enablement for the claimed inventions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

According to applicants comments in the interviews of February 17 and 22, 2000, based on the Horan et al. reference it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane. The prior art rejection has been dropped based on this interpretation of the Horan et al. reference. During the interview, BPS Schwartz inquired that in lieu of this unpredictability, how many examples of lipidized proteins were disclosed in the specification. Applicant indicated that there were numerous examples in the specification. However, all of the examples disclosed in the specification use a single type of lipid to create lipidized proteins (eg. glycyldioctadecylamide). Thus, while applicant has argued that Horan et al. disclose that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins. The claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons. The claims also state that the lipidized protein localizes intracellularly. Therefore, the enablement provided in the specification is not commensurate with the scope of the claimed inventions because Horan et al. disclose that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins and the claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons.

Regarding applicants comments, the MPEP section 2164.03 (Rev. 1, Feb. 2000)

states:

*However, in applications directed to inventions in arts where the results are unpredictable, the disclosure of a single species usually does not provide an adequate basis to support generic claims. In re Soll, 97 F.2d 623, 624, 38 USPQ 189, 191 (CCPA 1938). In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). This is because it is not obvious from the disclosure of one species, what other species will work.*

Applicant has already previously argued that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane. The instant specification only provides examples using a single type of lipid of a single size. According to applicants comments in the interviews of February 17 and 22, 2000, based on the Horan et al. reference it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane. The prior art rejection has been dropped based on this interpretation of the Horan et al. reference. During the interview, BPS Schwartz inquired that in lieu of this unpredictability, how many examples of lipidized proteins were disclosed in the specification. Applicant indicated that there were numerous examples in the specification. However, all of the examples disclosed in the specification use a single type of lipid to create lipidized proteins (eg. glycyldioctadecylamide). Thus, while applicant has argued that Horan et al. disclose that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins. The claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons. The claims also state that the lipidized protein localizes intracellularly. Therefore, the enablement provided in the specification is not commensurate with the scope of the claimed inventions because Horan et al. disclose that

it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins and the claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons.

6. Claims 6 and 11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

7. No claim is allowed.

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may be left on the examiners voice mail service. If attempts to reach the

Serial No. 08/973576  
Art Unit 1644

6

examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1800

A handwritten signature in black ink, appearing to read 'R. Schwadron', written in a cursive style.

Ron Schwadron, Ph.D.  
Primary Examiner  
Art Unit 1644